Thalidomide and its analogues in the treatment of Multiple Myeloma

Experimental Hematology & Oncology

Saad Z Usmani²  Andrea Moran¹  Rashid Khan¹  Nabeel Chauhan²  Tahir Latif³ 

[1] Carolyn & Neag Comprehensive Cancer Center, Lea’s Center for Hematologic Disorders, University of Connecticut Health Center, Farmington, CT, USA;Myeloma Institute for Research & Therapy, University of Arkansas for Medical Sciences, 4301 W. Markham Street, Little Rock, AR, USA;UC Cancer Institute, Division of Hematology-Oncology, University of Cincinnati School of Medicine, Cincinnati, OH, USA

关键词: Therapy;    Pomalidomide;    Lenalidomide;    Thalidomide;    Multiple Myeloma;   

Others  :  814651
DOI  :  10.1186/2162-3619-1-27

 received in 2012-07-17, accepted in 2012-08-29,  发布年份 2012

【 摘 要 】

Multiple myeloma is an incurable malignant disorder of mature B-cells that predominantly affects the elderly. The immunomodulatory drug (IMiD) thalidomide and its newer analogs demonstrate increased antitumor activity, and have had a positive impact on the natural history of multiple myeloma. Recent advances in the clinical application of these agents and in our understanding of their mechanism of action, and toxicity have made safer and smarter use of these drugs possible. This review discusses the available information regarding mechanisms of action, toxicity and clinical results on thalidomide, lenalidomide and pomalidomide in the therapy of multiple myeloma.

【 授权许可】

   
2012 Latif et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Kyle RA, Rajkumar SV: Multiple Myeloma. N Engl J Med 2004, 351:1860-1873.
• [2]Siegel R, Ward E, Brawley O, Jemal A: Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011, 61:212-236.
• [3]Solly S: Remarks on the pathology of mollities ossium with cases. Med Chir Trans 1844, 27:435-498. 8
• [4]Durie BGM, Salmon SE: The current status and future prospects of treatment for multiple myeloma. Clinic in Haematology 1982, 11:181-210.
• [5]Blokhin N, Larionov L, Perevodchikova N, Chebotareva L, Merkulova N: Clinical Experiences With Sarcolysin In Neoplastic Diseases. Ann N Y Acad Sci 1958, 68:1128-1132.
• [6]Mass RE: A comparison of the effect of prednisone and a placebo in the treatment of multiple myeloma. Cancer Chemother Rep 1 1962, 16:257-259.
• [7]Sporn JR, McIntyre OR: Chemotherapy of previously untreated multiple myeloma patients: an analysis of recent treatment results. Semin Oncol 1986, 13:318-325.
• [8]Singhal S, Mehta J, Desikan R, et al.: Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999, 341:1565-1571.
• [9]Dimopoulos MA, Anagnostopoulos A, Weber D: Treatment of plasma cell dyscrasias with thalidomide and its derivatives. J Clin Oncol 2003, 21:4444-4454.
• [10]Richardson P, Schlossman R, Jagannath S, et al.: Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity. Mayo Clin Proc 2004, 79:875-882.
• [11]Rajkumar SV, Rosinol L, Hussein M, et al.: Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol 2008, 26:2171-2177.
• [12]Anderson KC: Lenalidomide and thalidomide: mechanisms of action--similarities and differences. Semin Hematol 2005, 42(4 Suppl 4):S3-S8. Review
• [13]Dimopoulos M, Spencer A, Attal M, et al.: Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007, 357:2123-2132.
• [14]Weber DM, Chen C, Niesvizky R, et al.: Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007, 357:2133-2142.
• [15]Kumar S, Dispenzieri A, Lacy MQ, et al.: Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia 2007, 21:2035-2042.
• [16]Popat U, Saliba R, Thandi R, et al.: Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. iol Blood Marrow Transplant 2009, 15:718-723.
• [17]Attal M, Lauwers-Cances V, Marit G, et al.: Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 2012, 366(19):1782-1791.
• [18]McCarthy PL, Owzar K, Hofmeister CC, et al.: Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012, 366(19):1770-1781.
• [19]Palumbo A, Hajek R, Delforge M, et al.: Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 2012, 366(19):1759-1769.
• [20]Palumbo AP, Delforge M, Catalano J, et al.: The incidence of second primary malignancies (SPM) in melphalan-prednisone-lenalidomide combination followed by lenalidomide maintenance (MPR-R) in newly diagnosed multiple myeloma patients (pts) aged 65 or older. J Clin Oncol 2011, 29:8007.
• [21]Rossi AC, Mark TM, Jayabalan D, et al.: Incidence of second primary malignancies (SPM) after 6-years follow-up of continuous lenalidomide in first-line treatment of multiple myeloma (MM). J Clin Oncol 2011, 29:8008.
• [22]Dimopoulos MA, Orlowski RZ, Niesvizky R, Lonial S, Brandenburg NA, Weber DM: Lenalidomide and dexamethasone (LEN plus DEX) treatment in relapsed refractory myeloma (RRMM) patients and risk of second primary malignancy (SPM): Analysis of MM-009/010. J Clin Oncol 2011, 29:8009.
• [23]Schey SA, Fields P, Bartlett JB, et al.: Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol 2004, 22:3269-3276.
• [24]Lacy MQ, Hayman SR, Gertz MA, et al.: Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol 2009, 27:5008-5014.
• [25]Streetly MJ, Gyertson K, Daniel Y, Zeldis JB, Kazmi M, Schey SA: Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation. Br J Haematol 2008, 141:41-51.
• [26]Richardson P, Siegel D, Baz R, et al.: A Phase1/2 muti-center, randomized, open label dose escalating study to determine the maximum tolerated dose, safety, and efficacy of pomalidomide alone or in combination with low-dose dexamethasone in patients with replased and refractory mutiple myeloma who have received prior treatment that includes lenalidomide and bortezomib. Blood 2009, 114:301.
• [27]Hideshima T, Chauhan D, Shima Y, et al.: Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000, 96:2943-2950.
• [28]Niwayama S, Turk BE, Liu JO: Potent inhibition of tumor necrosis factor-alpha production by tetrafluorothalidomide and tetrafluorophthalimides. J Med Chem 1996, 39:3044-3045.
• [29]Chauhan D, Hideshima T, Rosen S, Reed JC, Kharbanda S, Anderson KC: Apaf-1/cytochrome c-independent and Smac-dependent induction of apoptosis in multiple myeloma (MM) cells. J Biol Chem 2001, 276:24453-24456.
• [30]Mitsiades N, Mitsiades CS, Poulaki V, et al.: Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood 2002, 99:4079-4086.
• [31]Corral LG, Haslett PA, Muller G, et al.: Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 1999, 163:380-386.
• [32]Schafer PH, Gandhi AK, Loveland MA, et al.: Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J Pharmacol Exp Ther 2003, 305:1222-1232.
• [33]Davies FE, Raje N, Hideshima T, et al.: Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001, 98:210-216.
• [34]Zhu D, Carrol LG, Fleming YW, Stein B: Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. Cancer Immunol Immunother 2008, 57:1849-1859.
• [35]Dredge K, Marriott JB, Macdonald CD, et al.: Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer 2002, 87:1166-1172.
• [36]Lu L, Payvandi F, Wu L, et al.: The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Microvasc Res 2009, 77:78-86.
• [37]Escoubet-Lozach L, Lin IL, Jensen-Pergakes K, et al.: Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. Cancer Res 2009, 69:7347-7356.
• [38]Ito T, Ando H, Suzuki T, et al.: Identification of a primary target of thalidomide teratogenicity. Science 2010 Mar 12, 327(5971):1345-1350.
• [39]Girona AL, Mendy D, Miller K, et al.: Direct binding with cereblon mediates the antiproliferative action of lenalidomide and pomalidomide. Blood 2011, 118:738.
• [40]Zhu YX, Braggio E, Shi C, et al.: Cereblon expression is required for the anti-myeloma activity of lenalidomide and Pomalidomide. Blood 2011, 118:127.
• [41]Heintal D, Bolomsky A, Schreder M, et al.: High expression of thalidomide binding protein cereblon(CRBN) is associated with improved clinical response in patients with mutiple myeloma treated with lenalidomide and dexamethasone. Blood 2011, 118:2879.
• [42]Palumbo A, Facon T, Sonneveld P, et al.: Thalidomide for treatment of multiple myeloma: 10 years later. Blood 2008, 111:3968-3977.
• [43]Facon T, Mary JY, Hulin C, et al.: Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomized trial. Lancet 2008, 370:1209-1218.
• [44]Barlogie B, Anaissie E, van Rhee F, et al.: Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol 2007, 138(2):176-185.
• [45]Morgan GJ, Gregory WM, Davies FE, et al.: The role of maintenance thalidomide therapy in multiple myeloma: MRC myeloma IX results and meta-analysis. Blood 2012, 119:7-15.
• [46]Rajkumar SV, Jacobus S, Callander NS, et al.: Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010, 11:29-37.
• [47]Niesvizky R, Jayabalan DS, Christos PJ, et al.: BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. Blood 2008, 111:1101-1109.
• [48]Palumbo A, Falco P, Corradini P, et al.: Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA–Italian Multiple Myeloma Network. J Clin Oncol 2007, 25:4459-4465.
• [49]Richardson P, Lonial S, Jakubowiak A, et al.: Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma: Encouraging efficacy in high risk groups with updated results of a phase I/II study. Blood 2008, 112:92.
• [50]Richardson PG, Jagannath S, Jakubowiak AJ, et al.: Phase II trail of lenalidomide, bortezomib and dexamethasone in patients (pts) with replased and replased/refractory multiple myeloma (MM): Updated efficacy and safety data after >2 years of follow up. Blood 2010, 116:3049.
• [51]Jakubowiak AJ, Reece DE, Hofmeister CC, et al.: Lenalidomide, Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Updated Results of Phase I/II MMRC Trial. Blood 2009, 114:132.
• [52]Kumar S, Flinn IW, Richardson PG, et al.: Novel three- and four-drug combination regimens of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide, for previously untreated multiple myeloma: Results from the multi-center, randomized, phase 2 EVOLUTION study. Blood 2010, 116:621.
• [53]Lacy MQ, Hayman SR, Gertz MA, et al.: Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia 2010, 24:1934-1939.
• [54]Mikhael J, Rajkumar V, Roy V, et al.: Efficacy of pomalidomide plus low-dose dexamethasone in mutiple myeloma patients despite previous use of lenalidomide. J Clin Oncol 2011, 29:8067.
• [55]Tomer M, Rodriguez M, Shah M, et al.: ClaPD (Clarithromycin/ [Biaxin(R)], Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma. Blood 2011, 118:635.
• [56]Palumbo A, Larocca A, Carella A, et al.: A Phase I/II Study of Pomalidomide-Cyclophosphamide-Prednisone (PCP) in Patients with Multiple Myeloma Relapsed/Refractory to Lenalidomide. Blood 2011, 118:632.